Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01’s recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain following catar

Related Keywords

France ,Massachusetts Institute Of Technology ,Massachusetts ,United States ,Boston ,Switzerland ,Corey Davis ,Rebecca Weil ,Sylvia Cheung ,Oculis Holding Ag Nasdaq ,Novartis ,Nasdaq ,Princeton University ,Mckinsey Company ,Chief Commercial ,Chief Executive Officer ,Chief Commercial Officer ,Senior Vice President ,Global Marketing ,Massachusetts Institute ,Dry Eye Disease ,Iopharmaceutical Company ,Uculis ,Commercial Leadership ,Product Launch ,Ocular Surgery ,Ophthalmology ,